Be the first to like this
The IPO class of 2014 hit new benchmarks in terms of both the number of public listings (63) and proceeds raised (US$4.9 billion), outstripping the superlatives set in 2000-01 at the height of the genomics bubble. Forty-eight (76%) of the biotechs that debuted in 2014 garnered more than US$50 million in their initial offerings, while 17 (27%) cleared the US$100 million mark. Nearly 60% of new companies listed within or above their IPO ranges in 2014. As of 31 December 2014, 42% of the US biotechs that went public in 2014 were trading up relative to their initial offering prices.
To read more, go to the EY Life Sciences Vital Signs site: http://www.ey.com/GL/en/Industries/Life-Sciences/EY-vital-signs-2014-a-new-benchmark-year-for-biotech-ipos